Alexander M. Lesokhin
Ludwig Center at MSK
Ludwig Institute for Cancer Research
United States of America
I am a clinician in our center’s Immunotherapeutics Clinical Core and the hematologic oncology division. I have been involved in the development of cancer testis antigen vaccines for myeloma (MAGE-A3, CT7) and several immunomodulatory antibody clinical studies (anti-CTLA4, anti-PD-1, anti-CD137) for both solid and liquid tumors. I have taken a leading role in the development of biomarkers that might improve clinical outcome via risk adapted immunotherapy for cancer.
Clinical trials, immunotherapy, biomarkers
Lesokhin, Alexander M., et al. "Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment." Cancer research 72.4 (2012): 876-886.
Ansell, Stephen M., et al. "PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma." New England Journal of Medicine 372.4 (2015): 311-319.
Wolchok, Jedd D., et al. "Nivolumab plus ipilimumab in advanced melanoma." New England Journal of Medicine 369.2 (2013): 122-133.